Screener
NewAmsterdam Pharma Company NAMS Restricted Cash Current
Restricted Cash Current at other companies
Other financials
Where this comes from
Reported directly by NewAmsterdam Pharma Company in its filing.
Tagged under the XBRL concept us-gaap:RestrictedCashCurrent.
The source filing: NewAmsterdam Pharma Company’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:06 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333824
| Line item | June 30,2026 | December 31,2025 |
|---|---|---|
| Cash and cash equivalents | 424,151 | 490,002 |
| Prepayments and other receivables | 23,996 | 38,138 |
| Marketable securities, current | 209,703 | 146,239 |
| Restricted cash | 1,357 | 1,321 |
| Total current assets | 659,207 | 675,700 |
| Marketable securities, net of current portion | 44,409 | 92,609 |
| Property, plant and equipment, net | 411 | 383 |
| Operating right of use asset | 82 | 185 |
Item 1. Financial Statements.
FAQ
- What is NewAmsterdam Pharma Company's restricted cash current?
- NewAmsterdam Pharma Company (NAMS) reported restricted cash current of $1.36M in Q2 2026.
- What does restricted cash current mean?
- Restricted Cash Current as reported by NewAmsterdam Pharma Company N.V. Ordinary Shares.
Ask your AI about NewAmsterdam Pharma Company's restricted cash current.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude